Yu ping feng san for pediatric allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials.

Abstract

BACKGROUND:

The potential treatment effects and safety of Yu ping feng san (YPFS) for pediatric allergic rhinitis (PAR) patients have yet to be studied systematically.

OBJECTIVES:

To assess the effects and safety of YPFS for treat pediatric patients, allergic rhinitis.

METHODS:

We systematically searched PubMed, EMBASE (Excerpta Medical Database), Cochrane library, Chinese Cochrane Centre's Controlled Trials Register platform, Wanfang Chinese Digital Periodical and Conference Database, China National Knowledge Infrastructure Database, and VIP Chinese Science, from inception dates to November 1, 2019. Randomized controlled trials (RCTs) were included. The risk of bias in the trials was assessed in accordance with the Cochrane Handbook, version 5.1.0. RevMan 5.3 software was used to perform a meta-analysis. Grading of Recommendations Assessment, Development and Evaluation methodology was applied to evaluate the evidence quality for each outcome. The quality of evidence for each outcome measurement was low for 4 outcomes and very low for 5 outcomes.

RESULTS:

A total of 10 RCTs involving 1069 participants (3-15 years old) fulfilled the inclusion criteria. After exclusion, 8 RCTs were pooled for efficacy assessment. The overall efficacy evaluation result did not show benefit for the experimental group (relative risk 0.32, CI 95% 0.24-0.45; P = .98;) Investigation of variation of serum IgA, immunoglobulin E, IgG in three studies in 2 groups returned no statistical significance. YPFS gave relatively better safety (relative risk 0.29, CI 95% 0.14-0.58; P = .0005; Fig. S8, http://links.lww.com/MD/F751) and lower recurrence rates than did Western medical therapy.

CONCLUSIONS:

Current evidence cannot support the routine use of YPFS for treatment of PAR. This may be due to poor-quality study-design limitations of the included YPFS studies. Our data showed that the use of YPFS for PAR is relatively safe compared to Western medical therapy, but a conclusion could not be drawn because only 5 studies were analyzed. Every study suffered from some methodological limitation. Therefore, further large, rigorously-designed studies are necessary to determine conclusively the utility of YPFS in PAR.

• Authors: Yong Liao, Juan Zhong, Shuqin Liu, Menglin Dai, Yang Liu, Xinrong Li, Yepeng Yang, Dazheng Zhang, Dan Lai, Tao Lu, Qinxiu Zhang, Yu Zhao
• Journal: Medicine (Medicine (Baltimore)) Vol. 100 Issue 13 Pg. e24534 (04 02 2021) ISSN: 1536-5964 [Electronic] United States
• PMID: 33787571 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Drugs, Chinese Herbal
• yu ping feng san

Topics

• Adolescent
• Child
• Drugs, Chinese Herbal (therapeutic use)
• Female
• Humans
• Male
• Randomized Controlled Trials as Topic
• Rhinitis, Allergic (drug therapy)
• Treatment Outcome